Mycinib®

Dimer Pharmaceuticals is revolutionizing cancer and neurodegenerative disease treatment with its innovative “Oncodegenic Approach.” This strategy leverages the observed epidemiological connection between these conditions, where individuals with cancer often exhibit a reduced risk of neurodegenerative diseases and vice versa. This inverse relationship highlights shared biological pathways, such as MYC and p53, which regulate cell survival, proliferation, and degeneration. By targeting these overlapping mechanisms, Dimer uncovers untapped therapeutic opportunities to address challenging and underserved medical conditions.

The flagship program is a pilot of Dimer’s platform technology, focusing on MYC-N amplified pediatric tumors (Pediatric High-Risk Neural Tumors, or PHRNT). These aggressive, treatment-resistant cancers—including neuroblastoma, medulloblastoma, DIPG, and GBM—leave young patients with limited options and poor prognoses. At the core of this program is Mycinib (MY-sih-nib), a novel small-molecule therapeutic designed to disrupt MYC-N driven pathways, which are central to tumor progression. By targeting this previously undruggable oncogenic driver, Mycinib offers life-changing potential for these young patients and their families.

This pilot program addresses an urgent unmet need in pediatric oncology while also validating Dimer’s broader platform. The scalability of this approach extends beyond pediatric cancers to adult malignancies driven by MYC-N overexpression, such as small-cell lung cancer, as well as neurodegenerative diseases where these pathways are implicated. This adaptability underscores the platform’s potential to generate a pipeline of therapies with wide-reaching impact.